Cell viability assays using CellTiter‐Glo reagents showed that Gal9‐KO significantly sensitized tumor organoids harboring ALK translocation to crizotinib (organoid #2) or those with KRAS mutations (organoid #3) to cisplatin (Figure 2I–J). This evidence concerns the gene KRAS and neoplasm.